1. Data & Insights

Resetting the Walk-Away Price: How GoodRx Data Reveals New Realities of Prescription Abandonment

Written by Posted on Less than 0 min read

Today’s guest post is from Divya Iyer, SVP of Go-to-Market Strategy at GoodRx.

Divya shares new GoodRx data showing that out-of-pocket costs at the pharmacy counter remain a primary barrier to medication adherence. Despite the availability of manufacturer-sponsored support programs, many patients still abandon their prescriptions due to high costs.


To learn about GoodRx’s prescription abandonment solutions, download Reduce Rx Abandonment at the Pharmacy.

Read on for Divya’s insights.

Read more »

© 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute, an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only.

       
View Original Article
Member since
Expert insights from Dr. Adam J. Fein on pharmaceutical economics and the drug distribution system. https://www.drugchannels.net/
Do you like Drug Channels's articles? Follow on social!

More from Drug Channels

  1. Channel: Drug

Can Rite Aid Recover?

Last fall, poor ol’ Rite Aid finally succumbed to bankruptcy. It was pretty much the definition of an expected surprise. To get a comprehensive look at the company’s ever-declining fortunes, DCI rummaged around the compnay’s numerous bankruptcy filings. Below, you’ll find our review of Rite Aid’s current financial situation, shrinking store footprint, changing relationship with […]
2 min read
0
  1. Data & Insights

Innovative Models for Improving Access and Visibility for Specialty-Lite and Retail Therapies

Today’s guest post comes from Timothy Nielsen, Vice President of Customer Success at AssistRx. Timothy discusses the affordability and patient journey challenges of specialty-lite products for patients, manufacturers, and health care providers. He explains how AssistRx’s Advanced Access Anywhere (AAA) solution streamlines processes for specialty-lite products and facilitates enrollment via a digital hub. To learn more, […]
2 min read
0
  1. Data & Insights

Informa Connect’s Patient Support Services Congress

Informa Connect’s Patient Support Services Congress November 20-21, 2024 | Hilton Penn’s Landing, Philadelphia, PA Drug Channels readers save 10%* with code 24DC10. The Patient Support Services Congress is designed to help educate and share innovative program design, latest customer strategies and practical solutions to overcome complex access barriers, enhance program performance and deliver best-in-class […]
3 min read
0
  1. Corporate Strategy

Addressing Gaps in Access: Strategies to Optimize Your Prescription Journey

Today’s guest post comes from Catherine Wood Hill, SVP of Marketing at PHIL. Catherine reviews the prescription lifecycle from the perspectives of patients, providers, and manufacturers. She explains how manufacturers can support patients with clear comunication about their prescriptions. Catherine then outlines five strategies to help providers have more informed conversations with patients. To learn […]
2 min read
0
  1. Operations & Supply Chain

Five Crucial Trends Facing U.S. Drug Wholesalers in 2024 and Beyond

As regular readers of Drug Channels know, U.S. distribution and dispensing channels for prescription drugs are undergoing significant evolution and consolidation as the changing economics of pharmaceuticals challenge conventional business models. During this period of volatility, the core business model of the Big Three public pharmaceutical distribution companies—Cardinal Health, Cencora, and McKesson—remains intact. Put simply: […]
2 min read
0
  1. Trends & External Forces

Bracing for Impact: The Future of Hub, PAP, and Affordability Programs Under the Inflation Reduction Act

Today’s guest post comes from Chris Dowd, Senior VP of Market Development at ConnectiveRx. Chris explains how the Inflation Reduction Act of 2022 (IRA) will impact hub, patient assistance programs (PAP), and affordability programs. He discusses steps manufacturers can take to accommodate the anticipated budget reductions while maintaining access and affordability for patients. To learn […]
2 min read
0
  1. Trends & External Forces

Surprise! Thanks to the IRA, Part D Plans Will Prefer High-List, High-Rebate Drugs

Like many of you, I have believed that the Inflation Reduction Act of 2022 (IRA) will encourage Medicare Part D plans to adopt low-list-price products over their high-list/high-rebate counterparts, thereby popping the gross-to-net bubble. Actually, maybe not. Below, I explain why the IRA will encourage Part D plans to prefer high-list, high-rebate specialty drugs, even […]
2 min read
0
  1. Channel: Drug

What CVS Pharmacy’s New Cost-Plus Reimbursement Approach Means for PBMs, Pharmacies, Plan Sponsors, and Prescription Prices (rerun)

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: Drug Channel Implications of the Inflation Reduction Act. For more on acquisition cost reimbursement for pharmacies, see Sections 8.4. and 12.3.4. of our new 2024 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. Click here to see the original […]
3 min read
0
  1. Data & Insights

Bridging the Gap in Patient Support: How GoodRx is Revolutionizing Access to Specialty Meds

Today’s guest post is from Divya Iyer, SVP Go-to-Market (GTM) Strategy at GoodRx. Divya argues that patient support programs (PSPs) struggle with awareness and accessibility, preventing patients from fully benefiting from the financial and educational resources available to them. Divya discusses how integrating digital solutions from GoodRx can enhance engagement, streamline access to therapy, and […]
2 min read
0
  1. Sponsored

Repairing the Patient Journey: How Pharma Can Fix the Obvious–and Not So Obvious–Breaking Points of Nonadherence

Today’s guest post comes from Maria Kirsch, President, Patient Services, Krista Pinto, President, Deployment Solutions, and Mike Scott, Senior Vice President, Specialty Consulting at EVERSANA. Maria, Krista, and Mike discuss the key reasons why patients abandon drug therapy. They then describe EVERSANA’s approach for helping manufacturers and healthcare providers improve adherence and health outcomes. Learn […]
2 min read
0
  1. Media & Marketing

Drug Channels News Roundup, April 2025: Amazon Rx Update, Express Scripts’ Spend Trends, Gold Cards, and CMS Acronym Absurdity

Spring has officially arrived at Drug Channels’ worldwide headquarters in beautiful downtown Philadelphia. (Photo proof at right.) So, scurry over to this month’s curated crop of noteworthy news: Amazon Pharmacy is still coming for retail pharmacy Express Scripts revives its long-lost drug trend report Prior authorization gold cards: Progress or peril? Plus, MPPP or not MPPP? […]
2 min read
0
  1. Trends & External Forces

The Healthcare Innovation Company’s Value-Based Care Summit

The Healthcare Innovation Company’s Value-Based Care Summit In-Person Event | October 28 – 29, 2024 in Washington, DC Use promo code VBCDC to save $100. Register Today. Download the brochure. The Value-Based Care Summit, produced by The Healthcare Innovation Company (thINc), brings together healthcare providers, health plans, pharmaceutical companies/manufacturers, and regulatory and legislative leaders to […]
3 min read
0
  1. Media & Marketing

How Direct-to-Consumer Rx Platforms Help Patient Support Programs Succeed

Today’s guest post comes from Josh Bliss, Head of Pharma Solutions at SingleCare. Josh outlines manufacturers’ challenge when educating and informing patients about patient support programs. He then describes the SingleCare prescription discount card and Pharma Solutions, which provides manufacturers with a platform to reach patients. Click here to learn how manufacturers can advertise patient […]
2 min read
0
  1. Corporate Strategy

Meet the Four Executives Headlining the Drug Channels Leadership Forum

Good news, everyone! We have secured four outstanding fireside chat participants for our inaugural Drug Channels Leadership Forum, which will be held next March in Miami. I’ll be leading one-on-one conversations with each of these executives: Steven H. Collis, Chairman, President, and CEO, Cencora, Inc. Patrick Conway, MD, MSc, CEO, Optum Rx Frank Cunningham, Group […]
2 min read
0
  1. Partnerships & Alt Profit

New Survey Reveals Manufacturers’ Patient Services Priorities for 2024

Today’s guest post comes from Nasir Ali, Chief Product Officer at CareMetx. Nasir shares findings from CareMetx’s new 2024 Patient Services Report research study: Revealing Manufacturer Priorities: Patients Naturally Take Center Stage. As he explains, manufacturers want hub partners that can take a holistic approach and address each patient’s individual needs. Nasir also discusses how […]
2 min read
0
  1. Data & Insights

Transparency Shocker: Biosimilars Are Getting Cheaper—But Hospitals and Insurers Can Make Them Expensive

Here on Drug Channels, we have long highlighted the boom in provider-administered biosimilars. In contrast to the pharmacy market, adoption of these biosimilars is growing, prices are dropping, and formulary barriers continue to fall. Novel transparency information reveals that this good news doesn’t always translate into savings. Below, we rely on a unique data set […]
2 min read
0
  1. Trends & External Forces

PBM Power: The Gross-to-Net Bubble Reached $334 Billion in 2023—But Will Soon Start Deflating (rerun)

This week, I’m rerunning some popular posts while I prepare for Friday’s Drug Channels Outlook 2025 live video webinar. Click here to see the original post. As you reread the article below, note that some manufacturers have already announced wholesale acquisition cost (WAC) list price declines for 2025. Last week, the Federal Trade Commission (FTC) […]
3 min read
0
  1. Data & Insights

Unlocking the Gate: The Critical First 24 Hours of Patient Hub Engagement

Today’s guest post comes from Kristine McGaughey, Vice President, Implementation at ConnectiveRx and Sam Blake, SVP, Hub Product at ConnectiveRx. Sam and Kristine discuss the importance of the first 24 hours of a patient’s engagement with a hub services program. They outline five reasons why two components—patient enrollment and successful benefits verification—dictate the effectiveness of […]
2 min read
0
  1. Trends & External Forces

Why 340B Reform Could Happen in 2025 (video)

During my recent Drug Channels Outlook 2025 video webinar, I tackled a wide range of crucial topics—including the controversial 340B Drug Pricing Program. As I explain in this video excerpt, we may finally see reform of this rapidly expanding program. What’s more, implementing the Inflation Reduction Act will disrupt the current operations of the 340B […]
2 min read
0
  1. Data & Insights

The Promise of a Direct-to-Patient Model—Breaking Down What’s Really Needed for Better Patient Access

Today’s guest post comes from Greg Skalicky, President, EVERSANA and Faruk Abdullah, President, Professional Services & Chief Business Officer, EVERSANA Greg and Faruk walk through the marketplace pressures driving Direct-to-Patient commercialization models. They argue that a technology-enabled infrastructure,  combined with clinical and reimbursement support specialists, can improve  patients’ access to new therapies, shorten the time […]
2 min read
0
Next